Determine the necessary mass, volume, or concentration for preparing a solution.
NFATc1-IN-1 - ≥99% , CAS No.1912422-56-0
Disponible para pedir
GRADE & PURITY ≥99%
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
224,000+ productos de investigación · Triple ISO certified · COA & SDS Disponible para cada producto · Same-day shipping on in-stock items
Why this grade
≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Storage & shipping
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Literature proof
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Descripción general
NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC 50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research.
In Vitro
NFATc1-IN-1 (compound A04) (0-2.5 μM, 4 days) exhibits potent inhibitory activities on osteoclast formation and function, which eventually translates into decreased bone resorption. NFATc1-IN-1 (1.5-2.5 μM, 24 h) blocks NFATc1 nuclear translocation and decreases the level of NFATc1. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Osteoclast precursor RAW 264.7 cells Concentration: 0, 0.5, 1.0, 1.5, 2.0 and 2.5 μM Incubation Time: 4 days Result: Markedly reduced the number and size of red TRAP-positive multinucleated osteoclasts at concentrations of 1.5, 2.0, and 2.5 μM. Significantly inhibited formation of osteoclasts in a dose-dependent manner (at 1.5, 2.0 and 2.5 μM), while showing no cytotoxic effects towards osteoclast precursor cells at concentrations of as high as 2.5 μM. ImmunofluorescenceCell Line: RAW264.7 cells Concentration: 1.5 or 2.5 μM Incubation Time: 24 h Result: Blocked NFATc1 nuclear translocation and decreased the level of NFATc1.
Form:Solid
Specifications
Especificaciones y pureza
≥99%
Mecanismos bioquímicos y fisiológicos
NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC 50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1 . NFATc1-IN-1 can be used
Condiciones de almacenamiento de almacenamiento
Store at -20°C
Enviado en
Ice chest + Ice pads
Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.
Tipo de acción
INHIBITOR
Pureza
≥99%
Nombres e identificadores
| Peso molecular | 375.11 |
|---|
Documentation
📋 Safety Data Sheet (SDS)
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →✅ Certificate of Analysis (COA)
Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →🔬 Specification Sheet
Full quality attributes and acceptance criteria for this grade.
View spec sheet →Advanced Data
Certificados (CoA, COO, BSE/TSE y tabla de análisis)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Propiedades químicas y físicas
| Solubilidad | DMSO : 125 mg/mL (333.24 mM; Need ultrasonic) |
|---|
Calculadoras de soluciones
Reseñas
Reseñas de cliente
Remind me later
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
Copyright © 2023–present Aladdin Scientific Corp. All rights reserved.